Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma

IF 3.3 4区 医学 Q2 HEMATOLOGY Hematological Oncology Pub Date : 2024-12-08 DOI:10.1002/hon.70015
Hazim S. Ababneh, Chirayu G. Patel
{"title":"Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma","authors":"Hazim S. Ababneh,&nbsp;Chirayu G. Patel","doi":"10.1002/hon.70015","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>As indolent non-Hodgkin's lymphomas (iNHLs) are very radiosensitive, radiation treatment (RT) has been established as an essential curative and palliative modality for early and advanced stages of the disease. Several studies have explored the role of very low-dose RT for palliation in indolent non-Hodgkin's lymphomas, demonstrating that this approach can lead to high rates of local control, and thereby, help improve the quality of life for these patients. While the most common schedule of very low-dose RT used in the palliative setting is 4Gy in 2 fractions, which was established in the landmark FoRT trial, this requires patients to be available for two RT sessions, increasing the financial and opportunity costs for the patient. Currently, data regarding the use of a single fraction of very low-dose RT (4Gy) for treating iNHLs in the palliative setting is still lacking. In this viewpoint, we aim to draw attention to this approach, where we emphasize the need for further exploration of the single-dose fractionation schedule as a non-toxic, simple, and easy treatment approach for iNHLs, which would inform future clinical trials to investigate this dose/fractionation.</p>\n </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70015","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

As indolent non-Hodgkin's lymphomas (iNHLs) are very radiosensitive, radiation treatment (RT) has been established as an essential curative and palliative modality for early and advanced stages of the disease. Several studies have explored the role of very low-dose RT for palliation in indolent non-Hodgkin's lymphomas, demonstrating that this approach can lead to high rates of local control, and thereby, help improve the quality of life for these patients. While the most common schedule of very low-dose RT used in the palliative setting is 4Gy in 2 fractions, which was established in the landmark FoRT trial, this requires patients to be available for two RT sessions, increasing the financial and opportunity costs for the patient. Currently, data regarding the use of a single fraction of very low-dose RT (4Gy) for treating iNHLs in the palliative setting is still lacking. In this viewpoint, we aim to draw attention to this approach, where we emphasize the need for further exploration of the single-dose fractionation schedule as a non-toxic, simple, and easy treatment approach for iNHLs, which would inform future clinical trials to investigate this dose/fractionation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
由于惰性非霍奇金淋巴瘤(iNHLs)对放射线非常敏感,放射治疗(RT)已被确定为治疗早期和晚期淋巴瘤的一种重要的治愈和姑息方式。有几项研究探讨了极低剂量 RT 在姑息治疗惰性非霍奇金淋巴瘤中的作用,结果表明这种方法可实现较高的局部控制率,从而有助于改善这些患者的生活质量。虽然在姑息治疗中最常用的超低剂量 RT 计划是 4Gy 2 次分次注射,这是在具有里程碑意义的 FoRT 试验中确立的,但这需要患者接受两次 RT 治疗,从而增加了患者的经济成本和机会成本。目前,有关在姑息治疗中使用单次超低剂量 RT(4Gy)治疗 iNHL 的数据仍然缺乏。在这篇论文中,我们希望引起人们对这一方法的关注,并强调有必要进一步探索单剂量分次放射治疗计划,将其作为一种无毒、简单、方便的治疗 iNHLs 的方法,这将为未来研究这一剂量/分次放射治疗的临床试验提供依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hematological Oncology
Hematological Oncology 医学-血液学
CiteScore
4.20
自引率
6.10%
发文量
147
审稿时长
>12 weeks
期刊介绍: Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.
期刊最新文献
Post-CAR T-Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B-Cell Lymphoma Combining Total Metabolic Tumor Volume With Beta-2-Microglobulin Levels Predicts Outcomes in High-Burden Follicular Lymphoma Patients Long-Term Outcomes of Reduced-Toxicity Conditioning Using 8-Gray Total Body Irradiation, Fludarabine, and Cyclophosphamide in Children, Adolescents, and Young Adults With Hematological Malignancies Ceiling Effect of International Myeloma Working Group Frailty Score in Real-World Population of Older Adults With Cancer Hospital Palliative Care Team Consultations in Different Subgroups of Hematologic Malignancies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1